140 related articles for article (PubMed ID: 26761396)
1. Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines.
Vzorov AN; Wang L; Chen J; Wang BZ; Compans RW
Virology; 2016 Feb; 489():141-50. PubMed ID: 26761396
[TBL] [Abstract][Full Text] [Related]
2. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.
Cheng C; Xu K; Kong R; Chuang GY; Corrigan AR; Geng H; Hill KR; Jafari AJ; O'Dell S; Ou L; Rawi R; Rowshan AP; Sarfo EK; Sastry M; Saunders KO; Schmidt SD; Wang S; Wu W; Zhang B; Doria-Rose NA; Haynes BF; Scorpio DG; Shapiro L; Mascola JR; Kwong PD
PLoS One; 2019; 14(4):e0215163. PubMed ID: 30995238
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
4. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
5. [A novel immunization strategy to induce strong humoral responses against HIV-1 using combined DNA, recombinant vaccinia virus and protein vaccines].
Liu C; Wang SH; Ren L; Hao YL; Zhang QC; Liu Y
Bing Du Xue Bao; 2014 Nov; 30(6):645-51. PubMed ID: 25868279
[TBL] [Abstract][Full Text] [Related]
6. Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.
Elsayed H; Nabi G; McKinstry WJ; Khoo KK; Mak J; Salazar AM; Tenbusch M; Temchura V; Überla K
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743369
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
[TBL] [Abstract][Full Text] [Related]
8. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.
Chuang GY; Lai YT; Boyington JC; Cheng C; Geng H; Narpala S; Rawi R; Schmidt SD; Tsybovsky Y; Verardi R; Xu K; Yang Y; Zhang B; Chambers M; Changela A; Corrigan AR; Kong R; Olia AS; Ou L; Sarfo EK; Wang S; Wu W; Doria-Rose NA; McDermott AB; Mascola JR; Kwong PD
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295908
[TBL] [Abstract][Full Text] [Related]
9. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.
Quan FS; Sailaja G; Skountzou I; Huang C; Vzorov A; Compans RW; Kang SM
Vaccine; 2007 May; 25(19):3841-50. PubMed ID: 17320250
[TBL] [Abstract][Full Text] [Related]
11. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
12. Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines.
Temchura V; Überla K
Curr Opin HIV AIDS; 2017 May; 12(3):272-277. PubMed ID: 28422791
[TBL] [Abstract][Full Text] [Related]
13. [VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties].
Vzorov AN; Compans RW
Mol Biol (Mosk); 2016; 50(3):406-15. PubMed ID: 27414779
[TBL] [Abstract][Full Text] [Related]
14. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.
Visciano ML; Diomede L; Tagliamonte M; Tornesello ML; Asti V; Bomsel M; Buonaguro FM; Lopalco L; Buonaguro L
Vaccine; 2011 Jul; 29(31):4903-12. PubMed ID: 21596074
[TBL] [Abstract][Full Text] [Related]
15. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.
Medina-Ramírez M; Sanders RW; Sattentau QJ
Curr Opin HIV AIDS; 2017 May; 12(3):241-249. PubMed ID: 28422788
[TBL] [Abstract][Full Text] [Related]
16. Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.
Nadai Y; Held K; Joseph S; Ahmed MIM; Hoffmann VS; Peterhoff D; Missanga M; Bauer A; Joachim A; Reimer U; Zerweck J; McCormack S; Cope AV; Tatoud R; Shattock RJ; Robb ML; Sandstroem EG; Hoelscher M; Maboko L; Bakari M; Kroidl A; Wagner R; Weber J; Pollakis G; Geldmacher C
Front Immunol; 2019; 10():717. PubMed ID: 31105688
[No Abstract] [Full Text] [Related]
17. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
18. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.
Tong T; Crooks ET; Osawa K; Binley JM
J Virol; 2012 Apr; 86(7):3574-87. PubMed ID: 22301141
[TBL] [Abstract][Full Text] [Related]
20. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.
Sarkar S; Piepenbrink MS; Basu M; Thakar J; Keefer MC; Hessell AJ; Haigwood NL; Kobie JJ
Vaccine; 2019 Apr; 37(17):2322-2330. PubMed ID: 30926296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
